Current progress in medical mycology

Infections caused by fungi have recently attracted the attention of both clinicians and basic researchers given the heavy burden they represent for any health system. The mortality and morbidity rates associated to mycosis are progressively rising simply because some of these diseases are still negl...

Full description

Saved in:
Bibliographic Details
Other Authors Mora-Montes, Hector Manuel (Editor), Lopes-Bezerra, Leila M. (Editor)
Format Electronic eBook
LanguageEnglish
Published Cham, Switzerland : Springer, [2017]
Subjects
Medical mycology.
Mycology.
elektronické knihy
electronic books
Online AccessFull text
ISBN9783319641133
9783319641126
Physical Description1 online resource : illustrations

Cover

Table of Contents:
  • Preface
  • Contents
  • Contributors
  • Chapter 1: Introduction to Medical Mycology
  • 1.1 Definition and Structure
  • 1.2 Emergence of Challenge Due to Fungal Infections
  • 1.3 Spectrum of Fungal Infections
  • 1.3.1 Superficial Mycoses
  • 1.3.2 Invasive/Opportunistic Mycoses
  • 1.3.3 Endemic Mycoses
  • 1.3.4 Allergic Manifestations
  • 1.4 Classification
  • 1.5 Epidemiology of Fungal Infections
  • 1.5.1 Global Burden of Disease
  • 1.5.2 Predisposing Factors for Fungal Infections
  • 1.5.3 Geographical Distribution
  • 1.5.4 Community Acquired Fungal Infections1.5.5 Nosocomial Fungal Infections
  • 1.6 Fungal Infection Immunity and Pathogenesis
  • 1.6.1 Innate Immunity
  • 1.6.2 Adaptive Immunity
  • 1.6.3 Fungal Virulence
  • 1.6.4 Tissue Reaction
  • 1.7 Diagnosis of Fungal Infections
  • 1.7.1 Radiological Imaging
  • 1.7.2 Conventional and Culture Based Diagnosis
  • 1.7.3 Sepsis Biomarkers
  • 1.7.4 Serology
  • 1.7.5 Molecular Detection
  • 1.8 Treatment
  • 1.9 Fungal Vaccines
  • References
  • Chapter 2: Antifungal Drugs
  • 2.1 Polyenes (Amphotericin B Deoxycholate and Its Lipid-ÂƯAssociated Formulations)2.1.1 Amphotericin B Deoxicholate
  • 2.1.1.1 Chemical Structure
  • 2.1.1.2 Mechanism of Action
  • 2.1.1.3 Pharmacokinetics and Pharmacodynamics
  • 2.1.1.4 Spectrum of Activities and Resistance
  • 2.1.1.5 Clinical Uses
  • 2.1.1.6 Dosing
  • 2.1.1.7 Adverse Events and Toxicity
  • 2.1.1.8 Contraindication
  • 2.1.1.9 Drug Interactions
  • 2.1.1.10 Use in Special Population
  • 2.1.2 Lipid Formulations of Amphotericin B
  • 2.1.2.1 Dosing
  • 2.1.2.2 Adverse Events and Toxicity
  • 2.2 Triazole Antifungal Agents2.2.1 General Properties
  • 2.2.1.1 Chemical Structure
  • 2.2.1.2 Mechanism of Action
  • 2.2.1.3 Pharmacokinetics
  • 2.2.1.4 Spectrum of Activity and Resistance
  • 2.2.1.5 Clinical Utility
  • 2.2.1.6 Adverse Events and Drug Interactions
  • 2.2.1.7 Dosing and Administration. Use in Special Populations
  • 2.2.2 Individual Agents
  • 2.2.2.1 Itraconazole
  • 2.2.2.2 Fluconazole
  • 2.2.2.3 Voriconazole
  • 2.2.2.4 Posaconazole
  • 2.2.2.5 Isavuconazole
  • 2.2.3 Newer and Investigational Agents: Efinaconazole, Albaconazole, Ravuconazole and Others2.3 Echinocandins
  • 2.3.1 Chemical Structure
  • 2.3.2 Mechanism of Action
  • 2.3.3 Pharmacokinetics and Pharmacodynamics
  • 2.3.4 Spectrum of Activity and Resistance
  • 2.3.5 Clinical Uses
  • 2.3.6 Adverse Events and Toxicity
  • 2.3.7 Drug Interactions
  • 2.3.8 Use in Special Population and Dose Adjustments
  • 2.3.9 Adult Dosing
  • 2.3.10 New Echinocandin
  • 2.4 Flucytosine
  • 2.4.1 Chemical Structure
  • 2.4.2 Mechanism of Action

Similar Items